With IPO money, Neumora eyes deals as CEO brings M&A chops from roles at AbbVie, JP Morgan
Neumora Therapeutics, a brain disease biotech born out of stitching together multiple neuroscience startups, is looking to replicate its original playbook by complementing its seven-drug pipeline with external assets thanks to a September IPO and $520 million balance sheet.
The drugmaker already has its hands full with a trio of Phase III studies in major depressive disorder; multiple clinical trials being prepared for bipolar depression, schizophrenia and Alzheimer’s disease agitation next year; and an IND planned in ALS in the back half of 2024. But with runway into 2026, Neumora sees room for more.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.